NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
6.56
+0.87 (15.29%)
At close: Oct 7, 2026, 4:00 PM EDT
6.57
+0.01 (0.15%)
Pre-market: Oct 8, 2026, 4:00 AM EDT
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
30.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Aligos Therapeutics | 31.52M |
| Immutep | 13.79M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
| aTyr Pharma | 190.00K |
NXTC News
- 1 month ago - Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - PRNewsWire
- 2 months ago - NextCure reports Q2 EPS ($2.80), consensus ($1.92) - TheFly
- 2 months ago - NextCure Quarterly report: Q2 2026 - Filings
- 2 months ago - NextCure Earnings release: Q2 2026 - Filings
- 2 months ago - NextCure Slides: Corporate presentation - Filings
- 2 months ago - NextCure trading resumes - TheFly
- 2 months ago - NextCure trading halted, volatility trading pause - TheFly
- 2 months ago - Why Is Penny Stock NextCure (NXTC) Up Today? - TipRanks